<p>The paper considers the current views of the prevalence, clinical picture, approaches to the diagnosis and treatment of one of the most common<br />neurological complications of diabetes mellitus – diabetic polyneuropathy, and both its somatic and autonomous manifestations. Neuropathy is<br />most common in diabetic patients and its clinical forms reflect the severe course of diabetes mellitus and serve as an unfavorable prognostic sign<br />that is associated with an approximately 5-fold increase in mortality. At the same time, the timely detection and adequate correction of the manifestations of neuropathy may substantially improve quality of life in the patients. The possibilities of pathogenetic therapy for diabetic polyneuropathy associated mainly with the use of benfotiamine and alpha-lipoic acid, as well as symptomatic therapy for its individual manifestations<br />are considered.</p
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.